Cerus Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Cerus Corporation (Cerus) is a biopharmaceutical company engaged in the development and commercialization of the INTERCEPT Blood System. The INTERCEPT system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells included in donated blood components intended for transfusion. The company’s operations are spread across the US, Japan, Europe and Middle East. The company is headquartered at Concord, California, the US. In June 2009, the company entered into a research and development alliance with Grifols, S.A. for red blood cell treatment.

The Cerus Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.